Literature DB >> 18344028

[Optimizing systems of care for patients with acute myocardial infarction. STEMI networks, telemetry ECG, and standardized quality improvement with systematic data feedback].

Karl Heinrich Scholz1, Georg von Knobelsdorff, Dorothe Ahlersmann, Friederike K Keating, Jens Jung, Gerald S Werner, Rolf Nitsche, Holger Duwald, Reinhard Hilgers.   

Abstract

Rapid revascularization of the infarct-related artery importantly affects prognosis in the treatment of acute ST elevation myocardial infarction (STEMI). Treatment results can be improved significantly when a STEMI-specific structure of care is created and when systematic quality improvement measures are implemented. The necessary structural measures include establishing or participating in myocardial infarction networks. When local hospitals collaborate in a network, it becomes feasible to offer round-the-clock primary coronary intervention to patients of those participating hospitals that do not have a catheterization laboratory on site. Another important structural step is to acquire and install prehospital twelve-lead ECG systems capable of remote telemetric transmission. This provides a solid basis for diagnosing STEMI with speed and accuracy and can prove to be highly effective in anchoring the chain of alert and treatment. As a consequence, two important goals can be realized: (1) intentionally bypassing the non-interventional hospital, and (2) systematically bypassing the emergency room of the interventional center. Both of these measures entail important time savings. An efficient instrument for improving treatment times is the implementation of a standardized quality improvement process with formalized data collection and analysis as well as with systematic data feedback to all systems and individuals involved in the early phase of treating STEMI patients within the hospital network including the emergency medical responder systems. The positive effect of such data feedback on treatment quality is contingent on the perception by all those involved that the data obtained for each patient are absolutely valid. Thus, those data need to be verifiable and an independent monitoring process should be created.Furthermore, the systematic use of standardized risk scores should be promoted in an effort to compare and adjust patient risk when analyzing network data. It is critically important that all appropriate patients-including those with a high risk of mortality--have access to rapid interventional treatment. Only when the individual risk of treated patients is taken into account will it be possible to compare quality of care and mortality rates. In general, the comparison between different hospitals, systems and regions is highly problematic and not feasible without considering local factors. It harbors the danger of inducing changes in practice in order to compete rather than in order to advance patient care, and thus it may be counterproductive when such a comparison leads to the implication that treatment may have been inferior. Therefore, the comparison of results (e.g., treatment times and mortality rates) should be undertaken as much as possible within an established system, with the use of a "before and after" design. Quality, then, will be defined as a documented consistent effort to improve results, and this approach will be distinctly productive. It is of fundamental importance that the involved hospitals, physicians and emergency staff perceive themselves as a team. The structures and processes outlined above can and should be applied broadly. The necessary resources will need to be provided through political and societal consensus. The multicenter FITT-STEMI project ("Feedback Intervention and Treatment Times in ST-Elevation Myocardial Infarction") is currently pursuing such an approach.

Entities:  

Mesh:

Year:  2008        PMID: 18344028     DOI: 10.1007/s00059-008-3120-6

Source DB:  PubMed          Journal:  Herz        ISSN: 0340-9937            Impact factor:   1.443


  9 in total

1.  [Telemedical prenotification in acute stroke treatment : Experiences from the Stroke Angel initiative from 2004 until the present].

Authors:  H Soda; V Ziegler; L Shammas; B Griewing; U Kippnich; M Keidel; A Rashid
Journal:  Nervenarzt       Date:  2017-02       Impact factor: 1.214

Review 2.  [Acute myocardial infarction: acute coronary intervention at any hospital versus acute coronary intervention at specialized centers only].

Authors:  Ralf Zahn; Uwe Zeymer
Journal:  Herz       Date:  2009-05       Impact factor: 1.443

3.  [Heart failure networks and centers : What does everyday life look like?]

Authors:  G Güder; G Ertl
Journal:  Herz       Date:  2018-09       Impact factor: 1.443

4.  [The White Paper on treating medical emergencies preclinically and at hospital : how can it be implemented?].

Authors:  G Scherer; T Luiz
Journal:  Anaesthesist       Date:  2011-08       Impact factor: 1.041

Review 5.  [Present and future relevance of telemedicine in cardiac arrhythmia emergencies].

Authors:  Jörg O Schwab; Thomas M Helms
Journal:  Herzschrittmacherther Elektrophysiol       Date:  2020-02-04

Review 6.  The quality of emergency medical care in baden-württemberg (Germany): four years in focus.

Authors:  Martin Messelken; Eduard Kehrberger; Burkhard Dirks; Matthias Fischer
Journal:  Dtsch Arztebl Int       Date:  2010-07-30       Impact factor: 5.594

7.  Factors that influence the acceptance of telemetry by emergency medical technicians in ambulances: an application of the extended technology acceptance model.

Authors:  Ji Young Hwang; Ki Young Kim; Kang Hyun Lee
Journal:  Telemed J E Health       Date:  2014-12       Impact factor: 3.536

8.  [Acute coronary syndromes without ST segment elevation].

Authors:  Helge Möllmann; Holger Nef; Christian W Hamm
Journal:  Herz       Date:  2009-02       Impact factor: 1.443

9.  Distinct features of recombinant rat vanilloid receptor-1 expressed in various expression systems.

Authors:  J Lázár; T Szabó; L Kovács; P M Blumberg; T Bíró
Journal:  Cell Mol Life Sci       Date:  2003-10       Impact factor: 9.261

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.